These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8349724)

  • 21. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
    Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
    Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity.
    Luo S; Martel C; Chen C; Labrie C; Candas B; Singh SM; Labrie F
    Urology; 1997 Dec; 50(6):913-9. PubMed ID: 9426723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'Casodex': defining the role of antiandrogens.
    McCaffrey JA; Scher HI
    Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
    [No Abstract]   [Full Text] [Related]  

  • 26. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
    Sarosdy MF
    Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.
    Tsukamoto S; Akaza H; Onozawa M; Shirai T; Ideyama Y
    Cancer; 1998 Feb; 82(3):531-7. PubMed ID: 9452271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 29. Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6-9, 1995.
    Urology; 1996 Jan; 47(1A Suppl):1-96. PubMed ID: 8560672
    [No Abstract]   [Full Text] [Related]  

  • 30. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY; Peehl DM; Navone NM; Feldman D
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative potency of bicalutamide (Casodex) and flutamide (Eulexin).
    Kolvenbag GJ; Furr BJ
    Urology; 1999 Jul; 54(1):194-7. PubMed ID: 10414753
    [No Abstract]   [Full Text] [Related]  

  • 32. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
    Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
    Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bicalutamide].
    Kotake T
    Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
    [No Abstract]   [Full Text] [Related]  

  • 35. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
    Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
    J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
    Lunglmayr G
    Horm Res; 1989; 32 Suppl 1():77-81. PubMed ID: 2515147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex.
    Tsukamoto S; Akaza H; Imada S; Koiso K; Shirai T; Ideyama Y; Kudo M
    J Natl Cancer Inst; 1995 Jun; 87(11):842-3. PubMed ID: 7791234
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
    Tyrrell CJ
    Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat.
    Chandolia RK; Weinbauer GF; Behre HM; Nieschlag E
    J Steroid Biochem Mol Biol; 1991 Mar; 38(3):367-75. PubMed ID: 1848993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of zindoxifene on experimental prostatic tumours of the rat.
    Schneider MR; Schiller CD; Humm A; von Angerer E
    J Cancer Res Clin Oncol; 1991; 117(1):33-6. PubMed ID: 1997466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.